Trial Profile
A pilot, open label, randomised clinical trial assessing the 12 week immunological response in HIV-1 failing subjects receiving monotherapy with emtricitabine 200 mg once a day or emtricitabine 200 mg once a week or lamivudine 300 mg once a day.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Jun 2011
Price :
$35
*
At a glance
- Drugs Emtricitabine (Primary) ; Lamivudine
- Indications HIV infections
- Focus Therapeutic Use
- Acronyms Break
- 07 Jun 2011 New trial record